Sichuan Goldstone Asia Pharmaceutical Inc (300434) Fair Value & Analysis
Industrials · CN · Market cap 3.7B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Share price +1.6% over the past month.
A solid business, but screening 40% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥8.60). The favourable scenario is already priced in.
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥6.80 – ¥21.04 · fair‑value band ¥4.80 – ¥8.60 · the ¥11.45 price screens above the ¥6.88 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Sichuan Goldstone Asia Pharmaceutical Inc (300434) currently trades at ¥11.45, while our model-based Fair Value estimate is ¥6.88, implying the stock looks roughly 39.9% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Sichuan Goldstone Asia Pharmaceutical Inc generated revenue of 1.1B CNY at a net margin of 17.1%. Revenue grew 13.7% year over year. It earns a return on equity of 7.0%. The balance sheet holds a net cash position of 341M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥4.80 (bear case) to ¥8.60 (bull case); at ¥11.45, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 31% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -35% fair-value upside, at -40%, 300434 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥7.24) versus Dividend Discount (¥1.08). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods.
Full company description
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sichuan Goldstone Asia Pharmaceutical Inc reported revenue of ¥1.0B in FY2025 versus ¥1.1B in FY2021, a compound −0.4%/yr. Reported net income was ¥132M in FY2025, compounding +18.6%/yr from FY2021.
300434 screens 40% overvalued. Compare with W.W. Grainger, Inc →
Peer Group
Industrial Distribution · 104 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Industrial Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Industrial Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| W.W. Grainger, Inc GWW | $1,376 | $625.61 | -55% |
| Fastenal Company FAST | $45.49 | $20.64 | -55% |
| Ferguson Enterprises Inc FERG | $232.02 | $151.92 | -35% |
| WESCO International, Inc WCC | $326.71 | $213.01 | -35% |
| Watsco, Inc WSO | $385.16 | $268.10 | -30% |
| Toromont Industries Ltd TIH | C$232.22 | C$127.90 | -45% |
| Applied Industrial Technologies, Inc AIT | $329.35 | $191.65 | -42% |
| Finning International Inc FTT | C$102.50 | C$76.38 | -25% |
| Addtech AB ADDTB | kr 329.20 | kr 156.35 | -53% |
| Core & Main, Inc CNM | $44.66 | $49.47 | +11% |
Compare Sichuan Goldstone Asia Pharmaceutical Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is Sichuan Goldstone Asia Pharmaceutical Inc (300434) overvalued or undervalued?
What is the fair value of 300434?
What is the quality score of 300434?
What is the revenue of Sichuan Goldstone Asia Pharmaceutical Inc (300434)?
What is the net profit margin of 300434?
Does Sichuan Goldstone Asia Pharmaceutical Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sichuan Goldstone Asia Pharmaceutical Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.